D Orazio & Associates Inc. Sells 145 Shares of DexCom, Inc. (NASDAQ:DXCM)

D Orazio & Associates Inc. decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,177 shares of the medical device company’s stock after selling 145 shares during the period. D Orazio & Associates Inc.’s holdings in DexCom were worth $1,017,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. ICICI Prudential Asset Management Co Ltd increased its holdings in DexCom by 19.8% during the third quarter. ICICI Prudential Asset Management Co Ltd now owns 5,231 shares of the medical device company’s stock valued at $351,000 after buying an additional 863 shares during the last quarter. Simmons Bank increased its holdings in DexCom by 9.2% during the third quarter. Simmons Bank now owns 4,095 shares of the medical device company’s stock valued at $275,000 after buying an additional 345 shares during the last quarter. Geneva Capital Management LLC increased its holdings in DexCom by 3.5% during the third quarter. Geneva Capital Management LLC now owns 130,668 shares of the medical device company’s stock valued at $8,760,000 after buying an additional 4,414 shares during the last quarter. Aigen Investment Management LP purchased a new stake in DexCom during the third quarter valued at approximately $349,000. Finally, Prime Capital Investment Advisors LLC purchased a new stake in DexCom during the third quarter valued at approximately $654,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on DXCM shares. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 target price on shares of DexCom in a report on Monday, August 26th. Robert W. Baird upped their target price on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Wells Fargo & Company upped their target price on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Oppenheimer reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Price Performance

DXCM traded down $1.97 during trading on Wednesday, hitting $72.37. 809,025 shares of the company traded hands, compared to its average volume of 3,903,180. The company has a market cap of $28.27 billion, a PE ratio of 44.52, a P/E/G ratio of 2.16 and a beta of 1.17. The stock’s 50-day simple moving average is $69.68 and its two-hundred day simple moving average is $92.63. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.